Get the Daily Brief
Latest Biotech News
J&J’s Dual-Target CAR-T Shows 100% Response in Phase 1b Trial
Johnson and Johnson reported a 100% objective response rate in relapsed/refractory large B-cell lymphoma patients with one prior therapy using its dual CD19/CD20-targeting CAR-T. The therapy...
ADC Therapeutics Shuts UK Site, Cuts 30% Workforce After Pipeline Losses
After discontinuing its only clinical-stage candidate, ADC Therapeutics announced closure of its UK R&D facility and a 30% staff reduction. Several early programs were halted to focus resources on...
FDA Approval Shifts Head and Neck Cancer Care Paradigm
The FDA has approved pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, marking the first checkpoint inhibitor approval in the...
Pivotal Clinical Data in Dual-Targeting CAR-T Cell Therapy for Lymphoma
Johnson and Johnson released encouraging phase 1b data for their dual-targeting CD19/CD20 CAR-T therapy in relapsed or refractory large B-cell lymphoma patients. The objective response rate was...
Financial Surge Follows Positive Hypertension Readout at Insmed
Insmed mailed a $750 million follow-on public equity offering following positive clinical data in hypertension. The financing round highlights growing investor confidence fueled by clinical...
Nonprofit Led by Anne Wojcicki Secures 23andMe Asset Acquisition
Former CEO Anne Wojcicki’s nonprofit, the TTAM Research Institute, won a second auction to acquire 23andMe’s assets for $305 million, surpassing Regeneron’s prior bid. Agreement includes...
Quantum Simulations Reveal Quasicrystal Stability Mechanisms
University of Michigan researchers conducted first quantum-mechanical simulations of quasicrystals, showing that these non-repeating atomic structures can be energetically stable. Employing...
New Rapid Method Enables Vascular Organoid Construction from iPSCs
Researchers reported a novel approach to generate functional vascular organoids by simultaneous activation of endothelial and mural lineage transcription factors ETV2 and NKX3.1. This method...
Emerging Biomarkers Predict Early Parkinson’s and Support Drug Repurposing
Two studies highlight advances in Parkinson’s research: one identifies perivascular fluid diffusivity as an early clinical progression biomarker using advanced MRI, enabling prognosis prior to...
Proteomics Integration Advances Multiomics Research Landscape
The integration of proteomics with DNA sequencing technologies is accelerating multiomics approaches in biological research. Collaborations between Ultima Genomics and Olink Proteomics, as well as...
FDA Moves Signal Enabling Expanded Uses and Regulatory Changes
Notable FDA news includes approval of Moderna’s RSV vaccine expansion to at-risk younger adults and Medtronic’s clearance of a miniature defibrillation lead for pediatric use. Additionally,...
AI Accelerates Scientific Communication and Drug Discovery Insights
Innovations in artificial intelligence are reshaping scientific communication and drug discovery. AI-generated podcasts are effectively summarizing complex cardiovascular nursing research, gaining...
FDA Clears Pembrolizumab for Resectable Head and Neck Cancer
The FDA approved pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, marking the first checkpoint inhibitor approval in this...
Wojcicki’s Nonprofit Tops Regeneron in 23andMe Bid
Anne Wojcicki’s nonprofit TTAM Research Institute secured 23andMe’s assets in a $305 million deal, outbidding Regeneron and committing to stringent privacy protections and continued data use for...
ADC Therapeutics Shuts UK Site, Cuts Workforce by 30%
After discontinuing its only clinical-stage candidate, ADC Therapeutics announced the closure of its UK R&D site and a 30% workforce reduction. The restructuring focuses resources on approved...
FDA Approvals and Regulatory Updates: Head and Neck Cancer, Bladder Cancer, RSV
The FDA has approved pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma patients with PD-L1 expression, based on the KEYNOTE-689 Phase 3 trial demonstrating...
23andMe Asset Acquisition: Anne Wojcicki’s Nonprofit Bid Wins
A bidding war for 23andMe culminated with former CEO Anne Wojcicki’s nonprofit, TTAM Research Institute, winning the auction with a $305 million offer that surpasses Regeneron’s $256 million bid....
Parkinson’s Disease: Multi-Omics Treatment, Subtype Correlates, and Brain Impairments
New Parkinson’s disease research highlights drug repurposing opportunities through integrative multi-omics analysis revealing memory-enhancing effects of meclofenoxate hydrochloride. Studies...
Cancer Therapy Advances: Novel Combinations and CAR-T Improvements
A recent early-phase trial combining revumenib, a menin inhibitor, with established AML treatments showed promising remission rates in genetically defined acute myeloid leukemia patients, leading...
Quantum and Optical Technology: Optical Clocks and Brain Imaging Breakthroughs
An international collaboration achieved the most extensive simultaneous comparison of optical atomic clocks across six countries, paving the way to redefine the second and enabling new...